Literature DB >> 23295932

Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.

Dong-Gun Lee1, Yoichi Murakami, David R Andes, William A Craig.   

Abstract

Reduced bactericidal efficacy at a high inoculum is known as the inoculum effect (IE). We used neutropenic mice to compare the IEs of ceftobiprole (CFB), daptomycin (DAP), linezolid (LZD), and vancomycin (VAN) against 6 to 9 strains of Staphylococcus aureus and 4 strains of Streptococcus pneumoniae at 2 inocula in opposite thighs of the same mice. Neutropenic mice had 10(4.5) to 10(5.7) CFU/thigh (low inoculum [LI]) in one thigh and 10(6.4) to 10(7.2) CFU/thigh (high inoculum [HI]) in the opposite thigh when treated for 24 h with subcutaneous (s.c.) doses every 12 h of DAP at 0.024 to 100 mg/kg of body weight and LZD at 0.313 to 320 mg/kg and s.c. doses every 6 h of CFB at 0.003 to 160 mg/kg and VAN at 0.049 to 800 mg/kg. Dose-response data were analyzed by a maximum effect (E(max)) model using nonlinear regression. Static doses for each drug and at each inoculum were calculated, and the difference between HI and LI (IE index) gave the magnitude of IE for each drug-organism combination. Mean (range) IE indexes of S. aureus were 2.9 (1.7 to 4.6) for CFB, 4.1 (2.6 to 9.3) for DAP, 4.6 (1.7 to 7.1) for LZD, and 10.1 (6.3 to 20.3) for VAN. In S. pneumoniae, the IE indexes were 2.5 (1.3 to 3.3) for CFB, 2.0 (1.6 to 2.8) for DAP, 1.9 (1.7 to 2.2) for LZD, and 1.5 (0.8 to 3.2) for VAN; these values were similar for all drugs. In S. aureus, the IE was much larger with VAN than with CFB, DAM, and LZD (P < 0.05). An in vivo time course of vancomycin activity showed initiation of killing at 4- to 16-fold-higher doses at HI than at LI despite similar initial growth of controls.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295932      PMCID: PMC3591865          DOI: 10.1128/AAC.00362-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.

Authors:  Karoline Sidelmann Brinch; Paul M Tulkens; Francoise Van Bambeke; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  J Antimicrob Chemother       Date:  2010-06-09       Impact factor: 5.790

Review 2.  Inoculum effect.

Authors:  I Brook
Journal:  Rev Infect Dis       Date:  1989 May-Jun

3.  The inoculum effect: fact or artifact?

Authors:  William A Craig; Sujata M Bhavnani; Paul G Ambrose
Journal:  Diagn Microbiol Infect Dis       Date:  2004-12       Impact factor: 2.803

4.  Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.

Authors:  Jack Brown; Kristen Brown; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  Limitations of vancomycin in the management of resistant staphylococcal infections.

Authors:  Marin H Kollef
Journal:  Clin Infect Dis       Date:  2007-09-15       Impact factor: 9.079

8.  Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes.

Authors:  Claudia Hawkins; Jenny Huang; Nancy Jin; Gary A Noskin; Teresa R Zembower; Maureen Bolon
Journal:  Arch Intern Med       Date:  2007-09-24

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Authors:  Dana Maglio; Christine Ong; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more
  22 in total

1.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.

Authors:  Nader Mroue; Anu Arya; Autumn Brown Gandt; Cameron Russell; Angel Han; Ekaterina Gavrish; Michael LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

3.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

4.  Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

Authors:  Jennifer Hoover; Thomas Lewandowski; Robert J Straub; Steven J Novick; Peter DeMarsh; Kelly Aubart; Stephen Rittenhouse; Magdalena Zalacain
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

5.  Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter.

Authors:  Wonhee So; Jared L Crandon; George G Zhanel; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

Review 6.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

7.  Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

Authors:  Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 8.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

9.  Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Authors:  Justin R Lenhard; Tanya Brown; Michael J Rybak; Calvin J Meaney; Nicholas B Norgard; Zackery P Bulman; Daniel A Brazeau; Steven R Gill; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

10.  Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models.

Authors:  Steven Boakes; William J Weiss; Mary Vinson; Sjoerd Wadman; Michael J Dawson
Journal:  J Antibiot (Tokyo)       Date:  2016-05-18       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.